Ready to turn a new page, Lan­dos Bio­phar­ma of­floads for­mer lead pro­gram to founder

Ear­li­er this year, au­toim­mune-fo­cused biotech Lan­dos Bio­phar­ma an­nounced that fol­low­ing a re­view of its pipeline, it will con­cen­trate on one of its clin­i­cal pro­grams and “ex­plore col­lab­o­ra­tions” for the rest.

New York-based Lan­dos has now found a new home for these can­di­dates: back in the arms of its founder and for­mer CEO, Josep Bas­saganya-Ri­era.

The com­pa­ny is trans­fer­ring its whole LAN­CL port­fo­lio, in­clud­ing the Phase II pro­gram omi­lan­cor, Phase I drug LABP-104 and pre­clin­i­cal can­di­date LABP-111, to Bas­saganya-Ri­era, ac­cord­ing to a press re­lease. In an SEC fil­ing, Lan­dos re­vealed that Bas­saganya-Ri­era has formed a new com­pa­ny named NIm­mune Bio­phar­ma, which will now house those com­pounds.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER